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Abstract: In this study, the prevalence of HTL V -1 infection among the thalassemic patients was investigated. 
181 thalassemic patients whom referred to Talghani hospital during, Oct. 2004-Sep. 2005 were participated in 
this study. HTL V antibody was determined using ELISA technique. In this procedure (Diapron laboratory kit) 
HTLV, positive samples tested by HTLV-1 western blot (kit, 2.4) to confirm, ELISA positive samples and also 
to detect the HTLV types. From 181 thalassemic patients, 93 (51.4%) were males. The age rate of these ranged 
1-25 years, (mean of 14.11±6.5). Of these subjects 169 patients (93.4%) were received packet cell at least one 
mrite per month. 28(14.9%) of subjects were HTL V positive, while only 4.4% of them were confirmed by western 
blot and also for contamination with type-1 virus infection. Contamination with this virus increased, as the 
patients were getting older. The findings derived from this study indicated that among the thalassemic patients 
in Gorgan there were cases with HTL V-1, infection that was correlated with the other part of the cormtry. It is 
therefore concluded; that fwther comprehensive studies are required to identify infected blood donations by 
blood donors in Gorgan. 
Key words: HTLV-1 antibody, tlialassemic patients, ELISA, Western blo~ Gargan 
INTRODUCTION 	 The endemicity of HTL V -1 depends on various factors 
such as environmental, social, behavioral and health 
HTLV-1 infects I-cells and it easily can be factors (Farid and Shirdel, 1999). In endemic areas and in 
transmitted through blood and blood products such as regions where HTL V -1 is epidemic, seroconversion is 
whole Blood, packed cell and platelets; while there is not seen in 44-63% cases after receiving HTL V-1 infected 
any report of infection for the patients whom receive blood derivates. 
plasma (Tavanai Sani, 2001 ). 2/3 of people receiving According to the study in Khorasan province, 
contaminated blood acquire the infection and the virus one fifth of infected subjects are those people whom 
keeps itself permanent in the infected subjects. In human received blood more than once. It is suggested that all of 
this virus infects I -cells and subsequently this cells blood donors have to be examined for the HTL V-1 in 
become proliferated and specific immrmity against order, to prevent the transmission of this virus to other 
HTLV-1 is stimulated. Following this event, the immrme people after the performance of proper serologic tests 
system destroys I-lymphocytes, which express the (Tavanai Sani, 2001). It should be mentioned that there is 
surface viral antigens. Those I-lymphocytes that do not not any specific antivirus drug to cure the diseases. So 
express the antigens, remain alive, proliferate and may the only way is the preventative measure, such as 
cause leukemia. These viruses are distributed all over the dismantling the HTLV-1 positive blood component. 
world (South of Japan, Caribbean region, South of United The frequency of this virus among the families, with 
of States, some parts of Africa). infected members is high. As it was mentioned before 
Nowadays, this virus is known as an etiologic factor blood is one of the main ways for the virus transmission. 
for ALT and chronic degenerative neurologic called as Thalassemic patients that receive repeated blood 
TSP (tropical spastic paralysis) diseases (Farid and transfusions are considered high-risk targets in regard to 
Shirdel, 1999). Some studies showed that HTLV-1 is HTLV-1 infection. The region where this present study 
endemic in Mashhad and in the South of Khorasan in the was carried out was Golestan province neighboring the 
East oflran (Tavanai Sani, 2001; Farid and Shirdel, 1999). North Khorasan, which is an endemic area for this virus. 
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There are also some reports about the presence of this 
virus in Golestan province and as for as this virus 
increases the cancer risk and ALT, this study was set up 
to investigate the prevalence of HTL V -1 infection, among 
the thalassemia major patient in Gorgan. 
MATERIALS AND METHODS 
In this descriptive cross-sectional study, blood was 
taken from 181 thalassemic patients referred to Talghani 
hospital for receiving the periodical blood transfusion 
during, Oct 2004-Sep. 2005. The serum samples from the 
patient's blood was separated and kept frozen at -20°C. 
At the time of blood sampling, a questionnaire was filled 
for every patient containing the demographic and the 
required variable for this study. Enzyme Linked 
Immrmosorbant Assay (ELISA) technique was used to 
investigate the presence of HTL V -1 antibody against the 
virus. The positive test for HTLV-1 antibody, 
subsequently were followed up for fwi:her positive test 
confinnation and virus typing using the Western-Blot 
method (HTLV Blot 2.4. Genelab Diagnostic's Ltd.). The 
true positive tests and identified virus types were 
recorded. SPSS software was used to analyze the data, 
using statistical tests such as Chi-square test. 
RESULTS 
From 181 thalassemic patients whom referred to 
Talghani hospital in Gorgan, 93 patients (51.4%) and 88 
patients (48.6%) were male and female respectively. The 
age of these subjects were between 1-25 years with mean 
age of 14.11±6.5. 28 subjects live in the families of 6-9 
people and 153 live in families of2-5 people. The mean of 
family member was 4.23±1.44. From the 181 patients, 
169 subjects (93.4%) received packed cell only once a 
month. 86 patients had parents who had familial relation. 
The history of blood diseases was present among 
36 (19.9%) patients' families. 
ELISA test showed that out of 181 thalassemic 
patients 28 subjects (14.9%), were HTL V antibody 
positive, but the western Blot (as a confinnatory test for 
ELISA) confirmed only 8 true HTLV-1 positive cases 
(4.4%). 
The prevalence of HTLV-1 by West.em Blot tests 
according to the various ages are gathered in (Table 1), 
but the highest infection rate was shown among the age 
group of 21-25 years. The rate of infection cased by this 
virus in patients receiving packed cell components either 
once or twice a month was 4.1 and 8.3%, respectively. 
Table 1: Frequency of HILV-1 Antibody with Western blot test in age 
groups ofthalassemic patients in Gargan 
Western blot 
Positive No. Negative No. Total No. 
Variables (%1 (%1 (%1 
Age groups 1-5 15 (100.0) 15 (8.3) 
variables 6-10 1 (2.9) 34 (97.1) 35 (19.3) 
11-15 2 (4.3) 44 (95.7) 46 (26.4) 
16-20 3 (4.8) 60 (95.2) 63 (34.8) 
21-25 2 (9.1) 20 (90.9) 22 (12.2) 
Total No. (%) 8 (4.4) 173 (95.6) 181 (100.0) 
DISCUSSION 
The findings from this study showed tha~ 4.7% of 
the thalassemic patients had HTLV-1 antibody using 
western Blot technique. These results are in partial 
agreement with other studies carried out both in Iran and 
other parts of the world (Italy) 4.8% (Agliano et al., 1998), 
Shiraz (Iran), 3.12% (Sot.oodeh and Tabei, 1994), Shiraz 
(Iran) 3% (Arjmandi, 2001), Hormozgan (Iran) 3.7% 
(Pour Karim et al., 2004). Findings of present study did 
not correlate with other studies that was carried out on 
thalassemic patients (New York 6.12% (Jason et al., 1985), 
Cecil 6.5% (de Mont.alembert et al., 1993), Vietnam 9.1 % 
(Lin eta!., 1997), Italy 2.7% (Mozzi eta!., 1992), Shiraz 
(Iran) 25.5% (Ghaderi and Agahi, 1996), Isfahan (Iran) 
2.7% (Moaiedi et al., 2000), Sist.an and Bluchest.an (Iran) 
1.6% (Moradi et al., 2002). Despite of different. data 
reports in studied regions, it seems that there may be 
areas with higher prevalence rate of HTLV-1 in Iran than 
expected. Differences existing in the virus prevalence 
reports could be due to specific geographical regions, 
different laboratory technique for the identification of the 
antibody against virus, (mostly reported by ELISA 
method which should be confirmed by West.em Blot). The 
importance of Western Blot as a confirmatory test has 
been obvious regarding to studies performed in 
Hormozgan (South of Iran) which ELISA test indicated 
41 HTL V -1 antibody positive cases but Western Blot 
confirmed only 14 cases, or to present study which 
ELISA test was positive for 28 cases, but Western Blot 
confirmed only 8 cases with antibody against HTL V -1. 
Finally it should be mentioned that various studies on 
non-thalassemic patients in various regions could show 
different. data (Ajami et al., 2000), but it should be stated 
that all of the above studies were carried out on 
thalassemic patients. It can be concluded that, the 
presence of HTLV-1 contamination in thalassemic patients 
that are repeatedly receiving blood and blood products is 
an indication that, the HTL V -1 infection among the blood 
donors is existed. A study in Thailand showed that there 
was not any HTL V-1 infection among the thalassemic 
patients, because the blood donors did not have the 
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HTL V-1 infection (Chiewsilp et al., 1993). Present study 
showed that there between the thalassemic patients' 
gender in Gorgan and HTL V-1 infection, was not any 
statistical significant. In this study, the lowest and 
highest rates of infection were seen among the patients of 
0-5 years and 21-25 years old with 0 and 9.1 %, 
respectively. The reason for high rate of infection in 21-25 
age group may due to continues usage of blood or blood 
products in comparison with 0-5 years of age group. 
There were not any statistical correlation between 
infection with HTL V -1 and parents familial relationship, 
the history blood disease within the family, thalassemic 
patient in the family and the number of people in one 
family, but the endemicity of HTLV-1 depends on the 
environmental, social, behavioral and hygienic factors 
(Farid and Shirdel, 1999). There is not any specific 
antiviral treatment of the infection. The only preventative 
measure is to identify and dismantling the infected blood 
derivates that are seropositive for the HTL V -1. Blood is 
one of the main sources of the virus transmission, among 
people receiving blood, or blood products. Thalassemic 
patients, that require repeated blood transfusions are 
high-risk individuals for HTL V -1 infection. In conclusion, 
the results of this investigation showed that the HTL V-1 
infection is not only confined to the endemic area, but the 
only way of virus transmission is not only blood 
products. In developing colllltries such as Iran, the 
principal way of transmission is through blood and blood 
products, therefore of is necessary, that all of the blood 
donors populations, should be investigated for HTL V-1 
as a preventative measure to stop keeping transmission of 
this virus to others people and thalassemic patients. 
Blood or blood products are remained the main risk 
factors for the transmission of this virus through blood 
transfusion, because there is not a blood screening 
procedure for the HTL V-1 in this region, therefore it is 
suggested that similar studies are required to have to a 
clear picture of the HTL V-1 infection within the Golestan 
province. 
REFERENCES 
Agliano, AM. and A Vania et al., 1998. Post 
transfusional hwnan retrovirus infection in 41 Italian 
beta-thalassemic patients. Haematologica, 77: 54-59. 
Ajami, A, RF. Hosseini and N. Tabarestain, 2000. 
Seroepidemiological smvey of HTL V-1/II in blood 
donors ofMazandaran in 1999. JMUSM., 26: 45-48. 
Arjmandi, F., 2001. HTLV-1 prevalence in patients with 
leukemia/lymphoma and normal population. Res. 
Med. Sci., 6 (2): 147-148. 
393 
Chiewsilp, P., W. larnsilp and P. Hathira~ 1993. HTL V-1 
antibody screening in donated blood and thalassemic 
patients. J. Med. Assoc. Thai. 76 (Suppl. 2): 103-105. 
de Montalembert, M. and D.G. Costagliola et al., 1993. 
Prevalence of markers for hwnan immllllodificiency 
virus type 1 and 2, hwnan T-lymphotropic virus type 
I, Cytomegalovirus and Hepatitis B and C virus in 
multiply transfused thalassemia patient. Transfusion, 
32: 509-512. 
Farid, R andA Shirdel, 1999. Phylogenetic ofHTLV-1 in 
Iranian born in Mashhad. Arch. Iran Med., 2: 24-25. 
Ghaderi, AA and M.H Agahi, 1996. High prevalence of 
anti-HCV and HTLV-1 antibodies in Thalassemia 
major patients of Southern Iran. Iranian J. Med. 
Sci , 2-1 (21) 60-62. 
Jason, J.M. and J.S. McDougal et al., 1985. Human I-cell 
Leukemia Virus (HTLV-l)P24 antibody in New York 
city blood product recipients. Am. J. Hematol., 
20: 129-137. 
Lin, M.T., B. T. Nguyen and T .V. Binh, 1997. Human 
T-lymphotropic virus type II infection in Vitnamese 
thalassemic patients. Arch. Virol., 142: 1429-1440. 
Moaiedi, B., AR Nafisi and K. Torabizadeh, 2000. 
Infection with HTL VI/II in thalassemia patients. 
Res. Med. Sci., 4 (I): 29-32. 
Moradi, A, Z.Y. Nezhad, AH. Mohagheghi, 
S.H Shahraki, A Borji, M.R Firoozkohi, 
E. Mirimoghadarn, M. Rakhshani and 
E.S. Moghadam, 2002. Seroepidemiology ofHTLV-1 
antibody in the thalassemic patients in Zahedan and 
Zaboul cities in 2001. J. Med. Univ. Sci. Zanjan, 
43: 43-47. 
Mozzi, F., P. Rebulla and F. Lillo, 1992. HIV and 
HTL V infections in 1305 transfusion-dependent 
thalassemic in Italy. AIDS, 6: 505-508. 
Pour Karim, MR, Gh.R Khamisi Pour, Gh.R Hajiani, 
R. Tahmasebi andA.N. Davani, 2004. Seroepidemio­
logical investigation of HTL V I/II infection among 
Bushehrian multi-transfused patients in 2003. Blood, 
2(4) 99-104. 
Sotoodeh, M. and S.Z. Tabei, 1994. Detection of human 
I -cell leukemia virus carriers in Thalassemia 
patients in Shiraz: A brief report. Iranian J. Med. Sci., 
2-1 (19) 14-12. 
Tavanai Sani, A., 2001. Serologic prevalence ofHTLV-1 
among blood donors in Mashhad (North Eastern of 
Iran). Arch. Iran Med., 4: 25-26. 
View publication stats 
